3378 — Hanx Biopharmaceuticals (Wuhan) Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$4.38bn
- HK$4.44bn
Annual balance sheet for Hanx Biopharmaceuticals (Wuhan) Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 204 | 174 | 652 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 299 | 243 | 692 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 24 | 24.1 | 19.9 |
| Net Intangible Assets | |||
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | 586 | 501 | 935 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 62.9 | 197 | 95.1 |
| Long Term Debt | |||
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Deferred Income Tax | |||
| Minority Interest | |||
| Total Liabilities | 318 | 335 | 238 |
| Common Stock | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 268 | 166 | 698 |
| Total Liabilities & Shareholders' Equity | 586 | 501 | 935 |
| Total Common Shares Outstanding |